Servicio de Alergia, Hospital Universitario Cruces, Barakaldo, Spain.
Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo, Spain.
Allergy. 2022 Dec;77(12):3641-3647. doi: 10.1111/all.15433. Epub 2022 Jul 20.
Iodinated contrast media produce non-immediate hypersensitivity reactions (NIHR). The goal of this prospective study was to determine the utility of skin tests and the subsequent tolerance to negative skin-tested iodinated contrasts in patients with NIHR caused by iomeprol.
Prick and intradermal tests with iomeprol, iopamidol, iopromide, and iobitridol were performed in all patients. IV challenge with the causative contrast (iomeprol in 90%) was made if skin tests were negative. In case of a positive skin test with the causal contrast, or a positive challenge test with it, IV challenge test with an alternative, negative skin-tested contrast was performed in all patients.
Skin tests were positive in 47.6% (20/42) of patients with NIHR induced by iomeprol. Of the 66 challenge tests performed with negative skin-tested iodinated contrasts, tolerance was confirmed in 35 (53%): 32 iomeron, 2 iobitridol, 1 iopamidol. Cross-reactivity between iomeprol and iopamidol was 22% (4/20 in patients with positive skin tests and 5/21 in patients with negative skin tests).
Sensitivity of the skin tests was less than 50% NIHRs due to iomeprol, while the negative predictive value of skin tests in patients who tolerated challenges with alternative contrasts (mainly iopamidol) was 53% (35 tolerated out of 66 performed). The cross-reactivity between iomeprol and iopamidol is high.
含碘造影剂可引发非即刻型过敏反应(NIHR)。本前瞻性研究旨在确定碘普罗胺所致 NIHR 患者的皮肤试验及其对阴性皮肤试验碘造影剂的后续耐受情况的实用性。
所有患者均进行碘普罗胺、碘帕醇、碘海醇和碘比醇的皮试和皮内试验。如果皮肤试验阴性,则进行导致 NIHR 的造影剂(90%碘普罗胺)的 IV 挑战。如果与致病对比剂的皮肤试验阳性,或阳性挑战试验,则对所有患者进行另一种阴性皮肤试验对比剂的 IV 挑战试验。
碘普罗胺所致 NIHR 患者中,47.6%(20/42)的皮肤试验阳性。在 66 次阴性皮肤试验碘造影剂的挑战试验中,有 35 次(53%)证实耐受:32 次碘美普尔,2 次碘比醇,1 次碘帕醇。碘普罗胺和碘帕醇之间的交叉反应率为 22%(20 例皮试阳性患者中有 4 例,21 例皮试阴性患者中有 5 例)。
碘普罗胺所致 NIHR 中皮肤试验的敏感性小于 50%,而在耐受替代对比剂(主要为碘帕醇)挑战的患者中,皮肤试验的阴性预测值为 53%(66 次试验中有 35 次耐受)。碘普罗胺和碘帕醇之间的交叉反应率较高。